[1]岳建和,张晓林,吉翔,等.联合搭桥手术治疗烟雾病的手术时机和疗效的相关性研究[J].第三军医大学学报,2020,42(03):294-299.
 YUE Jianhe,ZHANG Xiaolin,JI Xiang,et al.Correlation between operative timing and efficacy of combined bypass surgery for moyamoya disease[J].J Third Mil Med Univ,2020,42(03):294-299.
点击复制

联合搭桥手术治疗烟雾病的手术时机和疗效的相关性研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
42卷
期数:
2020年第03期
页码:
294-299
栏目:
神经科学
出版日期:
2020-02-15

文章信息/Info

Title:
Correlation between operative timing and efficacy of combined bypass surgery for moyamoya disease
作者:
岳建和张晓林吉翔蒋永祥陈晋程远
Author(s):
YUE Jianhe ZHANG Xiaolin JI Xiang JIANG Yongxiang CHEN Jin CHENG Yuan

Department of Neurosurgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China

关键词:
烟雾病手术时机联合手术搭桥Suzuki分期并发症手术疗效
Keywords:
 
分类号:
R181.31; R651; R743.4
文献标志码:
A
摘要:

目的对比Suzuki分期早期和晚期症状性烟雾病患者行联合搭桥手术的手术疗效,初步探讨症状性烟雾病患者手术时机和疗效的相关性。方法回顾性分析本科2015年6月至2018年10月收治的症状性烟雾病患者58例,共70侧半球。根据Suzuki分期,将患者分为早期组(Suzuki分期Ⅰ~Ⅲ期)和晚期组(Suzuki分期Ⅳ~Ⅵ期)。患者均行联合搭桥手术;分析两组患者围手术期并发症发生率、术后6个月改良Rankin量表(Modified Rankin Scale,mRS)评分、再次卒中、术后症状改善情况等差异。结果早期组围手术期总的并发症发生率、脑高灌注综合征及围手术期脑出血发生率明显低于晚期组(28.6% vs 57.1%、14.3 % vs 35.7%、0% vs 10.7%,P<0.05);早期组术后6个月mRS评分0~2分患者多于晚期组(85.7% vs 64.3%,P=0.036);两组术后症状改善率无明显差异(65.6% vs 68.4%, P=0.838);两组患者在术后随访过程中均未出现再次卒中。结论症状性烟雾病患者选择在Suzuki分期早期行搭桥手术,不仅可减少围手术期并发症发生,而且早期行手术治疗患者预后更好,可能为最佳搭桥手术时机。

Abstract:

Objective To compare the surgical efficacy of combined bypass surgery for symptomatic moyamoya disease patients at early and late Suzuki stage, and to preliminarily explore the correlation between operative timing and efficacy. MethodsA retrospective analysis was performed on 58 patients (70 hemispheres) with symptomatic moyamoya disease treated with combined bypass surgery in our department from June 2015 to October 2018. According to the results of Suzuki staging system for moyamoya disease, they were divided into early stage group (stage Ⅰ~Ⅲ, 42 hemispheres) and late stage group (stage Ⅳ~Ⅵ, 28 hemispheres). Superficial temporal artery-to-middle cerebral artery bypass with encephalo-duro-myo-synangiosis (STA-MCA bypass+EDMS) were performed for all patients. The perioperative complications, and improvement of symptoms, recurrence of stroke, and prognosis score (Modified Rankin Scale, mRS) in  6 months after the operation were assessed and compared between the 2 groups. Results The incidences of total perioperative complications, cerebral hyperperfusion syndrome and perioperative cerebral hemorrhage was significantly lower in the early stage group than the late stage group (28.6% vs 57.1%, 14.3% vs 35.7%, 0 vs 10.7%, respectively, P<0.05). There were more patients with mRS score of 0~2 at 6 months after surgery in the early stage group than those in the late stage group (85.7% vs 64.3%, P=0.036). No obvious difference was seen in the improvement rate of postoperative symptoms between the 2 groups (65.6% vs 68.4%, P=0.838). No stroke occurred in the both groups during postoperative follow-up. ConclusionBypass surgery can not only reduce the incidence of perioperative complications, but also obtain better prognosis for the early Suzuki stage patients with symptomatic moyamoya disease. Early Suzuki stage should be optimal operative time for bypass surgery.

参考文献/References:

[1]SUZUKI J, TAKAKU A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain[J]. Arch Neurol, 1969, 20(3): 288-299. DOI:10.1001/archneur.1969.00480090076012. 
[2]FUJIMURA M, TOMINAGA T. Hemorrhagic moyamoya disease: A recent update[J]. J Korean Neurosurg Soc, 2019, 62(2): 136-143. DOI:10.3340/jkns.2018.0101.
[3]王兆平, 刘洁一, 庄雷,等. 成人烟雾病的临床特点及预后与非遗传因素的相关性研究[J]. 中国现代医学杂志, 2015, 25(33): 1-7.
WANG Z P, LIU J Y, ZHUANG L, et al. Association of clinical features and prognosis with non-genetic factors in adult-onset moyamoya disease[J]. China J Mod Med, 2015, 25(33): 1-7.
[4]JEON J P, KIM J E, CHO W S, et al. Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults[J]. J Neurosurg, 2018, 128(3): 793-799. DOI:10.3171/2016.11.JNS161688.
[5]DING J Y, ZHOU D, PAUL COSKY E E, et al. Hemorrhagic moyamoya disease treatment: A network meta-analysis[J]. World Neurosurg, 2018, 117: e557-e562. DOI:10.1016/j.wneu.2018.06.076.
[6]JANG D K, LEE K S, RHA H K, et al. Bypass surgery versus medical treatment for symptomatic moyamoya disease in adults[J]. J Neurosurg, 2017, 127(3): 492-502. DOI:10.3171/2016.8.JNS152875.
[7]KIM T, OH C W, KWON O K, et al. Stroke prevention by direct revascularization for patients with adult-onset moyamoya disease presenting with ischemia[J]. J Neurosurg, 2016, 124(6): 1788-1793. DOI:10.3171/2015.6.JNS151105.
[8]周锡炜, 王建祯, 秦至臻. 烟雾病手术时机与术后并发症分析[J]. 中国实用神经疾病杂志, 2017, 20(5): 50-52.
ZHOU X W, WANG J Z, QIN Z Z. Surgical timing and postoperative complications of moyamoya disease[J]. Chin J Pract Nerv Dis, 2017, 20(5): 50-52. 
[9]ZHAO M, DENG X F, ZHANG D, et al. Risk factors for and outcomes of postoperative complications in adult patients with moyamoya disease[J]. J Neurosurg, 2018: 1-12. DOI:10.3171/2017.10.JNS171749.
[10]FUJIMURA M, TOMINAGA T. Diagnosis of moyamoya disease: international standard and regional differences[J]. Neurol Med Chir (Tokyo), 2015, 55(3): 189-193. DOI:10.2176/nmc.ra.2014-0307.
[11]XU B, SONG D L, MAO Y, et al. Superficial temporal artery-middle cerebral artery bypass combined with encephalo-duro-myo-synangiosis in treating moyamoya disease: surgical techniques, indications and midterm follow-up results[J]. Chin Med J, 2012, 125(24): 4398-4405.
[12]FUJIMURA M, MUGIKURA S, KANETA T, et al. Incidence and risk factors for symptomatic cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease[J]. Surg Neurol, 2009, 71(4): 442-447. DOI:10.1016/j.surneu.2008.02.031.
[13]WANG G Q, ZHANG X Y, FENG M Z, et al. Efficacy of surgical treatment on the recurrent stroke prevention for adult patients with hemorrhagic moyamoya disease[J]. J Craniofac Surg, 2017, 28(8): 2113-2116. DOI:10.1097/SCS.0000000000004004.
[14]MIYAMOTO S, YOSHIMOTO T, HASHIMOTO N, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan adult moyamoya trial[J]. Stroke, 2014, 45(5): 1415-1421. DOI:10.1161/STROKEAHA.113.004386.
[15]KURODA S, HOUKIN K. Moyamoya disease: current concepts and future perspectives[J]. Lancet Neurol, 2008, 7(11): 1056-1066. DOI:10.1016/S1474-4422(08)70240-0.
[16]QIAN C, YU X B, LI J R, et al. The efficacy of surgical treatment for the secondary prevention of stroke in symptomatic moyamoya disease: A meta-analysis[J]. Medicine (Baltimore), 2015, 94(49): e2218. DOI:10.1097/MD.0000000000002218.
[17]JANG D K, LEE K S, RHA H K, et al. Bypass surgery versus medical treatment for symptomatic moyamoya disease in adults[J]. J Neurosurg, 2017, 127(3): 492-502. DOI:10.3171/2016.8.JNS152875.
[18]VAN MOOK W N, RENNENBERG R J, SCHURINK G W, et al. Cerebral hyperperfusion syndrome[J]. Lancet Neurol, 2005, 4(12): 877-888. DOI:10.1016/S1474-4422(05)70251-9.
[19]ZHAO W G, LUO Q, JIA J B, et al. Cerebral hyperperfusion syndrome after revascularization surgery in patients with moyamoya disease[J]. Br J Neurosurg, 2013, 27(3): 321-325. DOI:10.3109/02688697.2012.757294. 
[20]KAWAMATA T, KAWASHIMA A, YAMAGUCHI K, et al. Usefulness of intraoperative laser Doppler flowmetry and thermography to predict a risk of postoperative hyperperfusion after superficial temporal artery-middle cerebral artery bypass for moyamoya disease[J]. Neurosurg Rev, 2011, 34(3): 355-362; discussion 362. DOI:10.1007/s10143-011-0331-8.
[21]陈洋,何跃,于加省.烟雾病颞浅动脉一大脑中动脉搭桥术后过度灌注综合征的研究进展[J]. 中华神经外科杂志, 2015,31(6):638-640.DOI:10.3760/cma.j.issn.1001-2346.2015.06.026.
CHEN Y, HE Y, YU J S. Research progress of hyperperfusion syndrome after superficial temporal artery-middle cerebral artery bypass grafting in moyamoya disease[J]. Chin J Neurosurg, 2015,31(6): 638-640. DOI:10.3760/cma.j.issn. 1001-2346. 2015.06.026.
[22]邱永逸, 陈劲草, 章剑剑, 等. 成人烟雾病STA-MCA分流术联合EMS后脑出血和高灌注综合征的关系[J]. 中国临床神经外科杂志, 2019, 24(7): 387-389. DOI:10.13798/j.issn.1009-153X.2019.07.002.
QIU Y Y, CHEN J C, ZHANG J J, et al. Relationship between postoperative intracranial hemorrhage and cerebral hyperperfusion syndrome after combined bypass in adult patients with Moyamya disease[J]. Chin J Clin Neurosurg, 2019, 24(7): 387-389. DOI:10.13798/j.issn.1009-153X.2019.07.002. 
[23]ISHIKAWA T, YAMAGUCHI K, KAWASHIMA A, et al. Predicting the occurrence of hemorrhagic cerebral hyperperfusion syndrome using regional cerebral blood flow after direct bypass surgery in patients with moyamoya disease[J]. World Neurosurg, 2018, 119: e750-e756. DOI:10.1016/j.wneu.2018.07.258. 
[24]SATOH S, SHIBUYA H, MATSUSHIMA Y, et al. Analysis of the angiographic findings in cases of childhood moyamoya disease[J]. Neuroradiol, 1988, 30(2): 111-119. DOI:10.1007/bf00395611.
[25]丁耀军, 谢安明. 成年人不同类型烟雾病的CT影像学表现[J]. 南昌大学学报(医学版), 2016, 56(6): 33-35, 49. DOI:10.13764/j.cnki.ncdm.2016.06.009.
DING Y J, XIE A M. CT imaging manifestations of different types of moyamoya disease in adults[J]. J Nanchang Univ Med Sci, 2016, 56(6): 33-35, 49. DOI:10.13764/j.cnki.ncdm.2016.06.009.

相似文献/References:

[1]叶嗣宽,赵攀,杨传利,等.耐多药肺结核早期外科治疗的临床效果分析[J].第三军医大学学报,2013,35(07):685.
[2]明萍,曾流芝,周斌.挫伤性前房积血继发青光眼62例临床分析[J].第三军医大学学报,2006,28(07):740.
[3]路星辰,董晨辉,杜全印,等.90岁以上髋部骨折患者不同手术时机的术后疗效分析[J].第三军医大学学报,2015,37(02):158.
 Lu Xingchen,Dong Chenhui,Du Quanyin,et al.Timing of surgery for hip fracture and outcomes in nonagenarians[J].J Third Mil Med Univ,2015,37(03):158.
[4]詹国清,董家鸿,王槐志,等.损伤性胆管狭窄手术时机探讨[J].第三军医大学学报,2002,24(09):0.[doi:10.16016/j.1000-5404.2002.09.060 ]

更新日期/Last Update: 2020-02-06